


RNA Based Therapeutic Market Projected to Reach \$4.35 Billion by 2030 with a CAGR of 17.6%

PORTLAND, OREGON, UNITED STATES,

June 17, 2024 /EINPresswire.com/ --

The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology. Moreover, Cancer diagnosis and treatment is currently undergoing a shift with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics, also for the diagnostic purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized.



The global [RNA based therapeutics market](#) size generated \$4,938.38 million in 2021, and is projected to reach \$25,121.95 million by 2030, growing at a CAGR of 17.6% from 2021 to 2030.

The global RNA therapeutics market is driven by the increasing number of government initiatives for large-scale sequencing projects, target specificity, and selectivity of treatment. However, the barriers to drug delivery, high research costs, and the risk of failure limit the market growth. On the other hand, capitalization of the pipeline therapeutics to the market will provide lucrative opportunities for market growth in the coming years.

Request Sample of the Report: <https://www.alliedmarketresearch.com/request-sample/546>

Key Takeaways:

The RNA interference (RNAi) segment, on the other hand, is expected to register the fastest CAGR of 18.8% throughout the forecast period.

the genetic disorder segment is also projected to manifest the fastest CAGR of 18.2% from 2021

to 2030.

The Asia-Pacific region is also expected to cite the fastest CAGR of 18.9% throughout the forecast period.

Research Institutes continue to maintain lead in the forecast year.

Market Dynamics:

Industry Investment

Venture Capital: Increasing investments in biotech firms specializing in RNA therapies.

Public Funding: Government and academic grants fostering RNA research and development.

Collaborations and Partnerships

Pharma-Biotech Collaborations: Strategic alliances for co-development and commercialization.

Academic and Industry Partnerships: Joint research initiatives accelerating innovation.

Patent Landscape

Intellectual Property Rights: Strong patents providing competitive advantage and market exclusivity.

Licensing Agreements: Revenue generation through licensing RNA technology platforms.

Recent Developments in the RNA Based Therapeutics Market

In June 2022, Alnylam Pharmaceuticals, Inc., one of the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA (vutrisiran), an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

In December 2021, Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, and Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, announced that the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of AB-729 for the treatment of hepatitis B. AB-729 is Arbutus's lead RNA interference (RNAi) therapeutic that is currently in multiple Phase 2a proof-of-concept clinical trials designed to evaluate it in combination with other approved or investigational agents.

Connect to our Analyst:

<https://www.alliedmarketresearch.com/connect-to-analyst/546>

RNA Based Therapeutic Market Segments:

By Type:

RNA Interference (RNAi)

RNA Antisense

APPLICATION

Genetic Disorders

Auto immune disorders

By END USER

Research Institutes

Hospitals & Clinics

By Region

North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, Spain, Rest of Europe)

Asia-Pacific (Australia, Japan, China, India, South Korea, Rest of Asia-Pacific)

LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Industry-Leading Players: -

Gradalis, Inc.

Arrowhead Pharmaceuticals

Arbutus Biopharma Corporation

Benitec Biopharma Inc.

Silence Therapeutics plc

Alnylam Pharmaceuticals, Inc.

Genzyme (Sanofi)

Ionis Pharmaceuticals

Sarepta Therapeutics

Biogen, Inc.

For Purchase Inquiry- <https://www.alliedmarketresearch.com/purchase-enquiry/546>

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global

enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/720554433>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.